The Frontier Trial – Field Randomization of NA-1 Treatment In Early Responders

Frontier Infographic

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset

A stroke is a brain attack. A stroke is caused by a sudden blockage of a blood vessel supplying the brain (ischemic), or bleeding into or around the brain (hemorrhagic). Most strokes (85%) are ischemic. Stroke should be treated as a medical emergency because there is a critical time, a “therapeutic window”, which may vary from minutes to a few hours in which a stroke can be reversed or mitigated. Acute ischemic stroke can be treated with medicines to unblock the artery and with urgent surgery to unblock the artery. Both are highly time sensitive treatments. The phrase “time is brain” emphasizes that brain tissue is rapidly and irretrievably lost as stroke progresses and that early intervention is critical to improve a stroke victim’s outcome. Medicines that could slow or halt the progression of damage to the brain after a brain artery is blocked could substantially benefit patients. This what NA-1 does. NA-1 is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered within three hours of symptom onset.

Study Objectives:

The main goal of the study is to determine the efficacy of NA-1 in reducing global disability in patients with acute stroke.

Other goals of the study are to determine the efficacy of NA-1 in:

• Reducing functional dependence.

• Improving neurological outcome.

• Increasing the proportion of aborted strokes.

• Improving activities of daily living.

CTV Launch Video – First responders treating stroke patients

Study website: or
Study Sponsor: NoNo Inc.

UPDATE: Voluntary suspension of enrolment since December 2015 to allow sites to address Health Canada Audit concerns.